Irinotecan for pediatric solid tumors: The memorial sloan-kettering experience

Maura Cosetti, Leonard H. Wexler, Elizabeth Calleja, Tanya Trippett, Michael LaQuaglia, Andrew G. Huvos, William Gerald, John H. Healey, Paul A. Meyers, Richard Gorlick

Research output: Contribution to journalArticle

62 Scopus citations

Abstract

Purpose Irinotecan is a novel antineoplastic agent that works by inhibiting the enzyme, topoisomerase 1. Although not extensively studied in children, preclinical studies and several phase 1 trials indicate activity against a variety of relapsed solid tumors when administered on a protracted schedule. This report describes an institutional experience with irinotecan for the treatment of pediatric solid tumors. Patients and Methods Twenty-two heavily pretreated children with multiply relapsed tumors were treated with courses of irinotecan at 20 mg/m2 per day for 10 days [(every day × 5) × 2]. Results Of the 19 patients evaluable for response, four achieved an objective response, including two complete responses and one partial response among four patients with rhabdomyosarcoma and one additional patient with an undifferentiated sarcoma with rhabdomyoblastic features, and one patient with a fibrosarcoma had stable disease. Among three patients with non-Hodgkin lymphoma, one achieved a partial response and one had stable disease. Diarrhea was the most commonly observed toxicity. Conclusion Irinotecan appears to have promising single-agent activity, particularly against rhabdomyosarcoma, with minimal hematopoietic toxicity, making it ideal for further evaluation in patients at high risk with newly diagnosed disease, particularly in combination with other active agents with nonoverlapping toxicities.

Original languageEnglish (US)
Pages (from-to)101-105
Number of pages5
JournalAmerican Journal of Pediatric Hematology/Oncology
Volume24
Issue number2
DOIs
StatePublished - Jan 1 2002

Keywords

  • Irinotecan
  • Pediatric malignancy
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Irinotecan for pediatric solid tumors: The memorial sloan-kettering experience'. Together they form a unique fingerprint.

  • Cite this

    Cosetti, M., Wexler, L. H., Calleja, E., Trippett, T., LaQuaglia, M., Huvos, A. G., Gerald, W., Healey, J. H., Meyers, P. A., & Gorlick, R. (2002). Irinotecan for pediatric solid tumors: The memorial sloan-kettering experience. American Journal of Pediatric Hematology/Oncology, 24(2), 101-105. https://doi.org/10.1097/00043426-200202000-00009